四硝酸季戊四醇酯对孕中期子宫胎盘灌注受损妊娠胎儿生长受限发生的影响——一项随机试验
这项多中心随机双盲安慰剂对照试验纳入317例孕19+0至22+6周平均子宫动脉搏动指数>95百分位的孕妇,比较四硝酸季戊四醇酯50mg每日两次与安慰剂。主要复合终点(围产期死亡或胎儿生长受限)发生率两组无显著差异(41.1% vs 45.5%,校正RR 0.90,95%CI 0.69-1.17,P=.43),但早产和妊娠期高血压发生率降低。
要点
- 孕中期子宫胎盘灌注受损孕妇中,四硝酸季戊四醇酯未显著降低围产期死亡或胎儿生长受限复合终点。
- 四硝酸季戊四醇酯组早产风险较安慰剂组降低(校正RR 0.73,95%CI 0.56-0.94,P=.01)。
- 四硝酸季戊四醇酯组妊娠期高血压风险较安慰剂组降低(校正RR 0.65,95%CI 0.46-0.92,P=.01)。
核心结论
- 研究未能显示四硝酸季戊四醇酯对孕中期子宫灌注受损孕妇胎儿生长受限和围产期死亡的发生有影响。
- 四硝酸季戊四醇酯显著降低了这些妊娠中早产和妊娠期高血压等次要结局参数的发生率。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,两组平行分组。
- 纳入孕19+0至22+6周平均子宫动脉搏动指数>95百分位的孕妇,随机接受50mg Pentalong或安慰剂每日两次。
- 2017年8月至2020年3月共纳入317例参与者,307例纳入分析。
主要发现
- 主要复合终点(围产期死亡或胎儿生长受限)累积发生率:四硝酸季戊四醇酯组41.1% vs 安慰剂组45.5%(未校正RR 0.90,95%CI 0.69-1.17;校正RR 0.90,95%CI 0.69-1.17;P=.43)。
- 早产:四硝酸季戊四醇酯组较安慰剂组降低(未校正RR 0.73,95%CI 0.56-0.94;校正RR 0.73,95%CI 0.56-0.94;P=.01)。
- 妊娠期高血压:四硝酸季戊四醇酯组较安慰剂组降低(未校正RR 0.65,95%CI 0.46-0.93;校正RR 0.65,95%CI 0.46-0.92;P=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fetal growth restriction is strongly associated with impaired placentation and abnormal uteroplacental blood flow. Nitric oxide donors such as pentaerythritol tetranitrate are strong vasodilators and protect the endothelium. Recently, we demonstrated in a randomized controlled pilot study a 38% relative risk reduction for the development of fetal growth restriction or perinatal death following administration of pentaerythritol tetranitrate to pregnant women at risk, identified by impaired uterine perfusion at midgestation. Results of this monocenter study prompted the hypothesis that pentaerythritol tetranitrate might have an effect in pregnancies with compromised placental function as a secondary prophylaxis. OBJECTIVE: This study aimed to test the hypothesis that the nitric oxide donor pentaerythritol tetranitrate reduces fetal growth restriction and perinatal death in pregnant women with impaired placental perfusion at midgestation in a multicenter trial. STUDY DESIGN: In this multicenter, randomized, double-blind, placebo-controlled trial, 2 parallel groups of pregnant women presenting with a mean uterine artery pulsatility index >95th percentile at 19+0 to 22+6 weeks of gestation were randomized to 50-mg Pentalong or placebo twice daily. Participants were assigned to high- or low-risk groups according to their medical history before randomization was performed block-wise with a fixed block length stratified by center and risk group. The primary efficacy endpoint was the composite outcome of perinatal death or development of fetal growth restriction. Secondary endpoints were neonatal and maternal outcome parameters. RESULTS: Between August 2017 and March 2020, 317 participants were included in the study and 307 were analyzed. The cumulative incidence of the primary outcome was 41.1% in the pentaerythritol tetranitrate group and 45.5% in the placebo group (unadjusted relative risk, 0.90; 95% confidence interval, 0.69-1.17; adjusted relative risk, 0.90; 95% confidence interval, 0.69-1.17; P=.43). Secondary outcomes such as preterm birth (unadjusted relative risk, 0.73; 95% confidence interval, 0.56-0.94; adjusted relative risk, 0.73; 95% confidence interval, 0.56-0.94; P=.01) and pregnancy-induced hypertension (unadjusted relative risk, 0.65; 95% confidence interval, 0.46-0.93; adjusted relative risk, 0.65; 95% confidence interval, 0.46-0.92; P=0.01) were reduced. CONCLUSION: Our study failed to show an impact of pentaerythritol tetranitrate on the development of fetal growth restriction and perinatal death in pregnant women with impaired uterine perfusion at midgestation. Pentaerythritol tetranitrate significantly reduced secondary outcome parameters such as the incidence of preterm birth and pregnancy-induced hypertension in these pregnancies.
引用
- Groten T, Lehmann T, Städtler M, et al. Effect of pentaerythritol tetranitrate (PETN) on the development of fetal growth restriction in pregnancies with impaired uteroplacental perfusion at midgestation-a randomized trial. Am J Obstet Gynecol. 2022. PMID: 35931132. doi:10.1016/j.ajog.2022.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。